Please use this identifier to cite or link to this item:
Title: Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)
Authors: HORWITZ, Steven M.SCARISBRICK, Julia J.DUMMER, ReinhardDUVIC, MadeleineKIM, Youn H.WALEWSKI, JanWHITTAKER, SeanQUAGLINO, PietroZINZANI, Pier LuigiWOLTER, PascalERADAT, HerbertSANCHES, Jose A.ORTIZ-ROMERO, Pablo L.AKILOV, Oleg E.TROTMAN, JudithTAYLOR, KerryDALLE, StephaneWEICHENTHAL, MichaelFISHER, David C.STADLER, RudolfFELDMAN, Tatyana A.KUZEL, Timothy M.GRU, Alejandro A.WANG, YinghuiPALANCA-WESSELS, Maria CorinnaLIN, Hui-MinLIU, YiLITTLE, MeredithPRINCE, H. Miles
Citation: BLOOD, v.130, suppl.1, 2017
Appears in Collections:

Comunicações em Eventos - FM/MDT
Departamento de Dermatologia - FM/MDT

Comunicações em Eventos - HC/ICHC
Instituto Central - HC/ICHC

Comunicações em Eventos - LIM/53
LIM/53 - Laboratório de Micologia

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.